nabu.science
MethodologyAboutContact

 

Reliability concern: This paper was retracted on 2023-06-21. See notice: 10.1155/2023/9809430.

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-B4500B1B·Framework v5.0·Pipeline v0.4·Evaluated 01 Jun 2026·OECD: 3.2 Clinical medicine·Subfield: Radiology, Nuclear Medicine and Imaging·Basis: Full text·Type: Diagnostic accuracy study

Diagnostic Value of Magnetic Resonance Susceptibility-Weighted Imaging Scanning in Different Types of Early Prostate Cancer.

Gao et al.Gao, Liu, Zhu·2022·Scanning·10.1155/2022/4884646 ↗

In brief

Correlational imaging observations in PSA-stratified prostate cancer patients, fatally undermined by paper mill indicators and absent diagnostic accuracy data.

ReliabilityConcerns4 of 4 checks completeRead the 3 entries ↓
Abstract

To investigate the cost of MRI-sensitive imaging (SWI) for early-stage prostate cancer. In 2019, the research group included a total of 60 leukemia patients, all of whom were diagnosed with prostate-specific antigen (PSA). According to the range of PSA values, they were group A (18 cases), group A 0-44 mg/ml (18 cases), and group B 4-1010 mg/ml (26 cases). 10 mg/ml was divided into C group (16 cases). Another 60 patients with benign prostatic hyperplasia treated at the same time served as a control group. All patients underwent sensitive MRI scanning, followed by diagnostic and clinical evaluation of weighted MRI scanning to diagnose various types of prostate cancer. The results showed that there was no difference in Ve levels among the three groups (P > 0.05); the SUSE score and Ktrans and Kep levels of the patients in group C were higher in groups B, A, and A (P < 0.05). In patients with early leukemia, SUSE score was significantly correlated with Ktrans and Kep levels (P < 0.05), but not with Ve and P > 0.05 levels. Magnetic resonance imaging can be used to diagnose prostate cancer. It can differentiate and diagnose different types of prostate cancer early. This is important for evaluating the benefits of prostate cancer screening and treatment.

Strengths · Limitations

Strengths

#application pathway

Addresses a clinically relevant diagnostic question

Prostate cancer diagnosis and early differentiation is a genuine clinical need with identifiable stakeholders including radiologists and urologists. The study targets a problem of real clinical significance.

↳ §1

#contribution

Biologically coherent discussion of SWI rationale

The discussion section provides a plausible mechanistic explanation for why SWI-related parameters (microvessel density, deoxyhemoglobin, magnetic susceptibility) would differ between malignant and benign prostate tissue.

↳ §4.3

#methodological rigour

Defined imaging protocol with scanner specifications

The methods section specifies the MRI scanner model, sequence parameters (TR, TE, matrix, FOV), contrast agent protocol, and SUSE scoring criteria, providing at least a formal methodological framework.

↳ §3.2

Limitations

#methodological rigour

Paper mill indicators and impossible statistics

The manuscript contains '[Journal]' placeholder strings throughout, refers to 'leukemia patients' in the abstract of a prostate cancer study, and reports a mathematically impossible control group age range (60–66 years, mean 50.2±5.4). These collectively suggest serious problems with manuscript integrity.

↳ §Abstract, §3.1, §3.2

#contribution

No diagnostic accuracy metrics despite diagnostic claims

Despite claiming to assess 'diagnostic value,' the paper reports no sensitivity, specificity, PPV, NPV, AUC, or any standard diagnostic performance metric. The findings are limited to group comparisons of imaging parameters across PSA levels.

↳ §4.1, §4.2, §5

#methodological rigour

Missing ethics approval and conduct safeguards

No ethics approval or institutional review board statement is present for a study involving human subjects undergoing MRI with intravenous contrast agent administration. No conflict of interest disclosure is provided.

↳ Full text — absent

Does this match your read? Add your assessment ↓

Withdrawn — shown for reference only

Nabu Commentary

This paper claims to evaluate the diagnostic value of MRI susceptibility-weighted imaging in early prostate cancer, but the reported evidence consists only of group comparisons of SUSE scores and DCE-MRI parameters (Ktrans, Kep, Ve) across PSA-stratified patient groups — no diagnostic accuracy metrics are presented. The manuscript contains multiple indicators of compromised integrity: '[Journal]' placeholder strings in the methods and discussion, 'leukemia patients' referenced in the abstract of a prostate cancer study, and a mathematically impossible control group age range. These issues, combined with the absence of ethics approval, absence of a limitations section, and fundamental misalignment between the stated research question and the reported data, result in very low scores across all dimensions. The biological rationale for SWI in prostate cancer presented in the discussion is coherent, but it cannot compensate for the paper's inability to deliver on its stated diagnostic purpose.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
1.1±0.2

Contribution
1.2

The paper claims to assess diagnostic value of SWI in prostate cancer but reports only correlational differences in SUSE scores and DCE-MRI parameters across PSA-stratified groups, without any diagnostic accuracy metrics. The mismatch between the stated aim and the actual evidence severely limits the identifiable advance.

§Title, §4.1, §4.2, §5

magnetic sensitive diffusion-weighted imaging can effectively identify the specific symptoms of patients

Methodological Rigour
0.9

The study design is fundamentally misaligned with the stated diagnostic research question: no reference standard, no sensitivity/specificity, and no ROC analysis are reported. Mathematically impossible statistics (control group age range 60–66, mean 50.2) and '[Journal]' placeholder strings raise questions about whether the methods were executed as described. The Red reliability flag would cap Methodological Rigour at 2.0, but the merit-based score of 0.9 is already below this threshold.

§3.1, §3.2, §4

Patients on the control group were 60-66 years of age and of median age (50.2 ± 5.4)

Reporting
1.5

The argument chain is disrupted by internal inconsistencies including disease label confusion in the abstract, incompatible group definitions between abstract and methods, and placeholder strings. Conclusions claim SWI can 'effectively identify specific symptoms' without supporting diagnostic accuracy data.

§Abstract, §3.1, §5
Positioning
1.7

The literature review in §2 cites relevant prior work on multiparametric MRI and PI-RADS, providing a recognizable conceptual backdrop. However, engagement with prior work is superficial, no limitations section is present, and the paper does not acknowledge that PSA-based grouping differs from histopathological classification.

§1, §2, §5

Reliability

Concerns4 of 4 checks


Internal CoherenceConcern

The paper contains multiple severe internal inconsistencies: the abstract refers to 'leukemia patients' in a prostate cancer study, PSA groupings differ between abstract and methods, a mathematically impossible age range is reported for the control group, '[Journal]' placeholder strings appear throughout, and PSA units are consistently wrong. These collectively indicate fundamental problems with manuscript integrity.

Research ConductConcern

No ethics approval or IRB statement is present despite the study involving human subjects undergoing MRI with contrast agent administration. No conflict of interest statement is provided. Data availability is claimed only upon request with no verifiable repository.

Flags: 1 declared / 5 total

Reference IntegrityClean

All 27 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordConcern

This paper was retracted on 2023-06-21. See notice: 10.1155/2023/9809430.

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cancer and neoplasms · Prostate cancer
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesMedium
CitationsFWCI 0.1
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The finding was demonstrated once in a single-hospital sample of 120 patients showing group differences and correlations, without any independent or multicentre confirmation.

From the paper
“It can differentiate and diagnose different types of prostate cancer early. This is important for evaluating the benefits of prostate cancer screening and treatment.”

The paper names a real-world diagnostic use for its findings but identifies no specific profession, organisation, or decision-maker who would apply them.

Pathway

Hospital radiology departments and urologists could incorporate SWI into prostate MRI protocols to noninvasively differentiate early cancer severity, guiding biopsy decisions and treatment selection.

Barrier

This single-centre study of 120 patients reports correlations but no validated diagnostic accuracy, so independent multicentre confirmation against histopathology is required before clinical adoption.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. How Does Diagnostic Accuracy Evolve with Increased Breast MRI Experience?

    Wu, Alikhassi, Curpen · 2023 · Clinical medicine

    Primary claim

    Diagnostic accuracy improved exponentially with increased MRI experience (definition B, OR of 1.27 and 1.61 for 5 and 10 years, respectively, p = 0.03 for both).

    Tentative
    Evidence Score
    2.3±0.1
    Reliability
    Caveats
  2. General cognitive function and the brain's structural connectome

    Buchanan, Moodie, Batziou, et al. · 2026 · Basic medicine

    Primary claim

    g is supported by a widely distributed white matter network whose macroscopic wiring capacity, microstructural organisation, and age sensitivity contribute in distinct ways.

    Tentative
    Evidence Score
    3.6±0.2
    Reliability
    Caveats
  3. The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network

    Markiewicz, Thompson, Wardlaw, et al. · 2026 · Clinical medicine

    Primary claim

    CL values across 74 scans showed excellent test-retest agreement (ICC = 0.968), improving to 0.987 after exclusion of one attenuation correction related outlier.

    Supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats

How the rubric works →